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Abstract: Drug-resistant Staphylococcus aureus is a continuing public health concern, 
both in the hospital and community settings. Antibacterial compounds that possess novel 
structural scaffolds and are effective against multiple S. aureus strains, including current 
drug-resistant ones, are needed. Previously, we have described the chrysophaentins, a 
family of bisdiarylbutene macrocycles from the chrysophyte alga Chrysophaeum taylori 
that inhibit the growth of S. aureus and methicillin-resistant S. aureus (MRSA). In this 
study we have analyzed the geographic variability of chrysophaentin production in  
C. taylori located at different sites on the island of St. John, U.S. Virgin Islands, and 
identified two new linear chrysophaentin analogs, E2 and E3. In addition, we have 
expanded the structure activity relationship through synthesis of fragments comprising 
conserved portions of the chrysophaentins, and determined the antimicrobial activity of 
natural chrysophaentins and their synthetic analogs against five diverse S. aureus strains. 
We find that the chrysophaentins show similar activity against all S. aureus strains, 
regardless of their drug sensitivity profiles. The synthetic chrysophaentin fragments indeed 
mimic the natural compounds in their spectrum of antibacterial activity, and therefore 
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represent logical starting points for future medicinal chemistry studies of the natural 
products and their analogs. 
Keywords: chrysophaentins; Staphylococcus aureus; antibacterial 
 
1. Introduction 
Staphylococcus aureus has long been a public health concern, and is currently the leading cause of 
skin, soft tissue, bloodstream, and lower respiratory tract bacterial infections [1]. Penicillin was 
discovered in 1928 and first used in 1941, but by the late 1940’s was ineffective due to the rise in 
penicillinase-producing S. aureus [2,3]. Methicillin was introduced into the clinic to combat  
penicillin-resistant strains, but not long after its introduction, the first case of methicillin-resistant  
S. aureus (MRSA) was described [4,5]. In the late 1980s and 1990s, the proportion of methicillin 
resistant infections rose significantly compared to susceptible ones worldwide [6]. In the United States,  
S. aureus is the leading cause of hospital-acquired infections [7]. Most of these strains are  
methicillin-resistant, and in the early 2000’s, more patients in the U.S. succumbed to lethal MRSA 
infections than to AIDS, tuberculosis, and hepatitis B combined [8]. 
The public health threat involving MRSA is not just limited to the spread of antibacterial resistance; 
the movement of MRSA infections out of hospital settings and into the community is of great concern. 
These community-associated MRSA (CA-MRSA) strains have become so prevalent in the United 
States that almost everyone can be considered at risk for these infections [9,10]. CA-MRSA infections 
present unique challenges to their treatment because they are distinct from hospital-acquired MRSA 
(HA-MRSA) from an epidemiological, genetic, and clinical perspective [11,12]. CA-MRSA strains 
generally have a faster growth rate than hospital acquired strains, but are less resistant to  
antibacterials [13]. These bacteria typically contain a type IV staphylococcal cassette chromosome mec 
type IV gene (SCC mec IV) and are capable of producing the extracellular cytotoxin Panton-Valentine 
leukocidin (PVL) [14,15]. In contrast, nosocomial S. aureus typically carry a type I, II, or III 
staphylococcal cassette chromosome mec. CA-MRSA is fully virulent, perhaps even more so than  
HA-MRSA, and can produce other toxins that vary by geographic location [16,17]. In the United 
States, there are two distinct community-associated backgrounds that comprise the majority of  
CA-MRSA infections, namely USA300 and USA400. USA400 was first identified, but for reasons not 
completely understood, USA300 has become the predominant infectious CA-MRSA clone [7,18,19], 
currently accounting for 90–95% of CA-MRSA outpatient isolates in the US [13,20,21]. One reason 
for its relative success and apparent fitness advantage may be its increased virulence. In a rat 
pneumonia model, researchers have shown increased pathogenicity that correlates with increased 
expression of virulence genes and increased expression of S. aureus regulatory systems [17,22]. 
The decline in antibacterial drug discovery programs worldwide has led to a concurrent decrease in 
the number of new antibacterial compounds [23]. This decline is apparent from the decrease in the 
number of antibacterial drugs (not including vaccines) approved for use from 1981–2010. During this 
period, 56 drugs were approved from 1981–1990, 32 were approved in 1991–2000, and only 16 were 
approved from 2001–2010 [24]. The increasing prevalence of resistance, even to drugs of last resort 
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such as vancomycin, indicates that more new compounds are still needed [25,26]. These trends, 
combined with the knowledge that while incremental changes to lead compound scaffolds that result in 
increased potency and spectrum generally do not provide a permanent solution to combating resistance, 
suggest that new antibiotic compounds should differ structurally from earlier generation antibacterials.  
Previously, we reported a suite of novel bisdiarlybutene macrocycles with antibacterial activity 
isolated from the marine chrysophyte alga, Chrysophaeum taylori, from St. John, U.S. Virgin Islands [27]. 
We found that these compounds have inhibitory activity against three drug-resistant Gram-positive 
organisms, and several drug-susceptible strains, and we developed a structure-activity relationship to 
explain their potencies. We made a subsequent collection from three locations on St. John, and have 
looked at geographic and temporal variability of chrysophaentin production. Furthermore, to address 
supply limitations of the natural products, we are working towards a total synthesis of the 
chrysophaentins, and have in hand two fragments from this effort. In this study, we have expanded the 
antibacterial activity and structure activity relationship of the natural chrysophaentins and two 
synthetic fragments to two additional S. aureus strains, S. aureus UAMS-1, a clinical osteomyelitis 
isolate, and CA-MRSA USA300-LAC. It was important to expand our library of S. aureus strains to 
include one with a more recent clinical, but still drug-susceptible, background, and a drug-resistant 
strain comprising the predominant and successfully invasive CA-MRSA USA300. We investigated the 
natural and synthetic chrysophaentin antibacterial activity to determine overall potency of growth 
inhibition and the mode of inhibition (bacteriostatic or bactericidal). 
2. Results and Discussion 
2.1. Chrysophaeum taylori Collection and Chrysophaentin Identification 
The original chrysophaentins came from one collection of C. taylori made in Round Bay, located on 
the southern side of St. John, U.S. Virgin Islands, in July 2007. From this collection, we identified four 
asymmetrically linked macrocycles, chrysophaentins A–D (1–4); one linear analog, chrysophaentin E (5); 
and three symmetrically-linked macrocycles, chrysophaentins F–H (8–10) (Figure 1). The eight 
chrysophaentins were remarkably similar to one another. All possess an ether linkage between C-1 and 
C-14′. If present, the second ether linkage was located between either C-14 or C-16 and C-1′, and 
halogen variability only occurred at C-2 and C-2′. Chrysophaentin H additionally differed in its 
pentahalogenation, with replacement of the hydrogen at C-12′ with a bromine. 
To obtain additional raw material, we returned to St. John in June 2009 and made three collections 
at Round Bay, Long Bay, and Hawk’s Nest (Figure 2). Each sample was dried and sequentially 
extracted with hexanes, chloroform, and methanol, and the chrysophaentins were found to be present 
in the methanol extract. Each methanolic extract from the three new collections plus the original 
collection were chromatographed by reverse-phase HPLC on a Jupiter Proteo C12 column with a 
linear gradient of 50–80% methanol in 0.05% TFA-water in fifty minutes. This afforded a 
chromatographic picture of the chrysophaentins present in each extract (Figure 3). The two collections 
from Round Bay (Figure 3A,C), separated by two years, were remarkably similar, as was the collection 
from Long Bay (Figure 3B). However, it was immediately obvious that the methanol extract from 
Hawk’s Nest (Figure 3D) was different; in fact, it lacked the asymmetrically-linked chrysophaentins 
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A–D. Instead, the linear chrysophaentin E was the most abundant, as well as two newly identified 
linear chrysophaentins, termed E2 and E3 (Figure 1, compounds 6 and 7). Algae collected from all 
locations contained the symmetrical chrysophaentins, albeit at much lower abundance relative to 
compounds A–E. 
Figure 1. Structures of the natural chrysophaentins and synthetic fragments. 
 
Figure 2. Locations of Chrysophaeum taylori collections on St. John, U.S. Virgin Islands. 
Collections were made Long Bay in 2009 (green pin), the northern tip of Round Bay in 
2007 and 2009 (yellow pin), and on the north side of the island at Hawk’s Nest in 2009 
(red pin). Image was created using the Google Earth software package [28]. 
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Figure 3. Geographic distribution of chrysophaentins determined by LCMS. Analytical 
HPLC chromatograms of MeOH extracts of four collections of Chrysophaeum taylori 
eluting with a linear gradient of 50–80% MeOH in aq. 0.05%TFA in 50 min. Panels 
correspond to C. taylori extracts obtained from the following collections sites and dates: 
(A) Round Bay, 2007; (B) Long Bay, 2009; (C) Round Bay, 2009; (D) Hawk’s Nest, 2009. 
The expansions shown correspond to the chromatograms at 28–42 min, and UV detection 
at 280 nm. Peaks are colored as shown in the legend, panel A.  
 
2.2. Identification of New Acyclic Chrysophaentins 
Previously we determined the structure of acyclic chrysophaentin E (5), which has a molecular 
formula of C32H26Cl4O8 as determined by HR-MS and NMR. Chrysophaentins E2 (6) and E3 (7) were 
obtained in insufficient quantities for full NMR characterization. However, through analysis of the 
respective fragmentation patterns observed in the HR-ESI-MS data, we were able to assign structures 
for each of these new linear chrysophaentins. HR-ESI-MS showed chrysophaentin E2 to possess a 
molecular formula of C32H26BrCl3O8 (m/z 720.9786 [M − H]
−
, calcd for C32H25BrCl3O8, 720.9798), 
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and chrysophaentin E3 to possess a molecular formula of C32H26Br2Cl2O8 (m/z 764.9282 [M − H]
−
, 
calcd for C32H25Br2Cl2O8, 764.9293), indicating that a bromine replaced a chlorine in E2 (6), and two 
bromines replaced two chlorines in E3 (7), when compared to chrysophaentin E (5). Since positions  
C-2 and C-2′ were the only sites of halogen variability in the natural chrysophaentins, we reasoned that 
the dibrominated compound 7 likely contained a bromine at both of these carbons. On the other hand, 
chrysophaentin E2 must contain bromine at only one of these sites, with chlorine at the other. To 
identify the respective locations of chlorine and bromine in 6, we compared the mass fragmentation 
patterns of the three linear analogs (Figure 4). As seen in Figure 4A, the fragmentation pattern for 
chrysophaentin E showed the successive loss of four chlorine atoms, giving fragment ions with clear 
isotopic signatures at m/z 641 [M − H − HCl]−, 605 [M − H − 2HCl]−, 569 [M − H − 3HCl]−, and  
533 [M − H − 4HCl]−. The fragmentation pattern and peak intensities for chrysophaentin E2 (6) was 
very similar to 5 (Figure 4A and 4B), where successive loss of three chlorines and one bromine gave 
rise to fragment ions at m/z 685 [M − H − HCl]−, 649 [M − H − 2HCl]−, 613 [M − H − 3HCl]−, and  
533 [M − H − HBr − 3HCl]−. In contrast, although loss of two bromines and two chlorines  
was apparent in the mass spectrum for chrysophaentin E3, the major ion for 7 appeared at  
m/z 395 [M − H − HBr − HCl − C16H14O3]
−
, which corresponds to the fragment generated from 
cleavage at the ether bond (Figure 4C). Although MS data on model halogenated biaryl ethers was not 
available, our data suggest that the presence of bromine ortho to the ether bond is destabilizing as 
compared to chlorine in the same position, and facilitates cleavage at the ether bond in compound 7. 
Thus, the nearly identical mass spectral patterns observed for 5 and 6, and the unique fragmentation at 
the ether bond in the spectrum for 7, allow assignments of the structures of the new linear 
chrysophaentins E2 and E3, as shown in Figures 1 and 4. 
Figure 4. HR-MS fragmentation of chrysophaentins E, E2, and E3. Fragmentation of  
(A) chrysophaentin E showing individual losses of four chlorine atoms; (B) chrysophaentin 
E2 showing loss of three chlorine atoms and one bromine atom; (C) the major ion in the 
spectrum for chrysophaentin E3 corresponds to fragmentation at the ether bond, with 
weaker ions corresponding to loss of two chlorine and two bromine atoms. 
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Figure 4. Cont.  
 
2.3. Chrysophaentin Fragment Synthesis 
While the extracts from Long Bay and Round Bay afforded more of the asymmetrical 
chrysophaentins, it became apparent that a synthetic approach to chrysophaentin production was 
necessary in order to fully examine the biological activity of the structural variants. Accordingly, we 
devised a convergent synthetic strategy to allow for a total synthesis of the chrysophaentins as well as 
the investigation of structure-activity relationships. Fragment 12, which, in principle, could be used 
twice for the assembly of the diether 1, could be constructed by a key Negishi cross-coupling between 
vinyl iodide 13 and benzylic zinc species 14 (Scheme 1). A chloroiodination of alkyne 15 and a 
metalation of a halide derived from aldehyde 16 were envisioned to provide access to 13 and 14, 
respectively. In fact, while some modification of protective groups was required, this strategy could be 
readily realized. 
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Scheme 1. Retrosynthetic approach toward chrysophaentin A (1). 
 
The commercially available benzoic acid 17 was reduced with lithium aluminumhydride (LAH)  
to the benzylalcohol 18 (Scheme 2). Bromination [29] and copper-catalyzed substitution with  
TMS-acetylene magnesium bromide [30] provided the alkyne 20 in 89% overall yield from 17. After 
desilylation of 20 with tetrabutylammonium fluoride (TBAF), dimethyl resorcinol 15 was subjected to 
iodochlorination [31,32] in an attempt to generate 13. However, the desired alkyne addition product 
was formed to a minor extent, and mainly overiodination products were observed. Therefore, we 
demethylated 15 with boron tribromide and installed the deactivating pivaloyl esters in 82% yield. 
Iodochlorination of 21 now proceeded in excellent yield to give a 2:1 mixture of alkene isomers 22 and 
23. While this ratio could be further improved in favor of the (E)-alkene 22 using solvents other than 
dichloromethane, yields were considerably lower. Furthermore, we were unable to separate the mixture 
at this stage, and the clean conversion in dichloromethane allowed us to carry it forward to the 
coupling step. 
Scheme 2. Preparation of (E)-iodoalkene segment (22). 
 
Formylation [33,34] of dimethyl hydroquinone 24 provided aldehyde 16, which was reduced to the 
alcohol 25 and brominated to give 26 in high yield (Scheme 3). Four equivalents of this bromide were 
then converted to the corresponding zinc reagent. Removal of excess zinc was necessary prior to 
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combination with 22 and 23 and subsequent microwave heating in the presence of palladium acetate. 
These cross-coupling conditions [35] generated satisfactory yields of the chloroalkenes 11 and 27 in a 
2:1 ratio after methanolysis of the pivaloate esters with cesium carbonate and methanol. An analytically 
pure sample of 11 was obtained by separation with supercritical fluid chromatography (SFC). Boron 
tribromide was used to cleave the two methyl ethers on 11 to give the tetraphenol 12, which was 
obtained as the pure (E)-isomer and further purified by preparative supercritical fluid chromatography 
(SFC) before submission to biological testing. In a control experiment, the use of a 2:1 mixture of 11 
and 27 in the deprotection reaction led to a 2:1 mixture of 12 and its (Z)-diastereomer, as expected. 
The assignments of the E/Z-configurations of 12 and its (Z)-diasteromer as well as 22 and 23 were 
mainly based on the available literature data [31,32]. 
Scheme 3. Preparation of benzyl bromide segment (26) and Negishi coupling to give 
tetraphenol 12. 
 
2.4. Antibacterial Evaluation 
With the new fragments in hand, we tested whether their potencies were similar to the parent 
chrysophaentins. A microbroth dilution assay was used to evaluate the antibacterial activity of these 
compounds, and the minimum inhibitory concentration that led to a 50% decrease in growth (MIC50) 
was determined using a model curve fit to the data. The MIC90 was determined as the lowest 
concentration where there was no visible growth, and the minimum bactericidal concentration (MBC) 
was determined as the lowest concentration where a plated aliquot of treated bacteria led to a three 
logarithmic decrease in colony forming units (CFU) per milliliter relative to the starting inoculum.  
All compounds were evaluated against three different S. aureus strains from ATCC and two diverse 
clinical isolates. The strains used in this study included: S. aureus ATCC 25923, a clinical isolate from 
Seattle, 1945; methicillin-resistant S. aureus ATCC BAA-41, a hospital-acquired strain isolated in 
New York City in 1994; multidrug-resistant S. aureus (MDRSA) ATCC BAA-44, a hospital-acquired 
strain isolated in Lisbon, Portugal, with resistance towards ampicillin, methicillin, oxacillin, penicillin, 
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erythromycin, gentamicin, tetracycline, azithromycin, amikacin, clindamycin, cephalothin, ceftriaxone, 
imipenem, lincomycin, streptomycin, perfloxacin, rifampin, and neomycin [6,36]; S. aureus UAMS-1, 
a clinical osteomyelitis isolate [37]; and community-associated methicillin-resistant S. aureus, 
USA300-LAC [38,39]. 
2.4.1. Minimum Bactericidal Concentrations for Select Natural Chrysophaentins 
The MIC50 for select chrysophaentins was reported previously [27]. Those qualitative antibacterial 
data have been expanded here to include descriptions of the MIC90 and the MBC for the 
chrysophaentins against S. aureus 25923, MRSA BAA-41, and MDRSA BAA-44. These values are 
summarized in Table 1. We found chrysophaentin A to inhibit the growth of S. aureus 25923, MRSA 
BAA-41 and MDRSA BAA-44 with MIC50 values on the order of 1–4 μM, and MIC90 values ranging 
from 4–9 µM against all three strains. Chrysophaentin A was bacteriostatic at its MIC90, becoming 
bactericidal only at concentrations four to eight times higher than the MIC90. We have found 
chrysophaentin A to be the most potent compound in all of our antibacterial assays, yet chrysophaentins 
F and H which bear a symmetrical bisbibenzyl ether skeleton also inhibit S. aureus 25923 and MRSA 
BAA-41 with single digit micromolar MIC50s. While their MIC90s were higher than those of 
chrysophaentin A (17–19 µM), the MBC for chrysophaentin F was still four-fold higher than the 
MIC90. A significant reduction in potency was observed for the acyclic natural product chrysophaentin 
E (5), which was also bacteriostatic at its MIC90. Chrysophaentins D (4) and G (9), both of which 
contain a bromine atom on the D ring, were the least active compounds, with an 8- to13-fold increase 
in MIC50s values, and an 8-fold increase in MIC90s. 
Table 1. Antibacterial summary of select chrysophaentins and synthetic fragments  
against five diverse strains of Staphylococcus aureus (all values are in µM; n.d. means  
not determined). 
 S. aureus 25923 MRSA BAA-41 MDRSA BAA-44 S. aureus UAMS-1 
CA-MRSA  
USA300-LAC 
 MIC50 MIC90 MBC MIC50 MIC90 MBC MIC50 MIC90 MIC50 MIC90 MBC MIC50 MIC90 MBC 
1 2.7 ± 0.9 9.2 37 2.3 ± 1.0 4.6 37 1.8 ± 0.5 9.2 5.1 ± 2.1 9.2 19 5.0 ± 2.4 9.2 19 
4 37 ± 16 65 n.d. 26 ± 8.5 65 n.d. n.d. n.d. 49 ± 23 65 >65 41 ± 20 65 >65 
5 16 ± 5.3 37 74 14 ± 4.1 37 74 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
8 7.9 ± 2.9 19 74 6.3 ± 1.9 19 74 n.d. n.d. 12 ± 5.6 37 >74 12 ± 5.1 37 74 
9 23 ± 7.5 69 n.d. 17 ± 4.3 69 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
10 5.9 ± 1.8 17 n.d. 6.2 ± 1.9 17 n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
11 12 ± 4.3 34 68 11 ± 5.4 34 68 13 ± 4.7 34 20 ± 10 34 68 18 ± 8.4 34 68 
12 20 ± 5.2 74 150 23 ± 9.9 74 150 27 ± 9.4 74 31 ± 13 74 150 29 ± 9.9 74 150 
2.4.2. Antibacterial Activity of Synthetic Chrysophaentin Fragments 
We were gratified to find that compound 11 inhibited the growth of S. aureus 25923 with MIC50 
and MIC90 values comparable to those for the linear and symmetrically linked natural products 5 and 8 
(Table 1). At the MIC90, compound 11 was bacteriostatic, and its MBC was 68 µM. Compound 11 also 
inhibited the growth of MRSA BAA-41 and MDRSA BAA-44 with low micromolar MIC50s, and an 
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MIC90 of 34 µM for both strains. Compound 12 was slightly less active with MIC50s in the range of 
20–28 μM against S. aureus 25923, MRSA BAA-41, and MDRSA BAA-44. An increase to 74 µM in 
MIC90 was observed for all three strains. Compound 12 was bacteriostatic at this concentration, with a 
MBC of ~150 µM.  
2.4.3. Antibacterial Activity against S. aureus UAMS-1 and CA-MRSA USA300-LAC 
Given the notable antibacterial activity observed for diverse laboratory strains of S. aureus, we were 
interested to compare the effects of several representative compounds on the clinical S. aureus strains 
UAMS-1 and CA-MRSA USA300-LAC. Compounds evaluated included chrysophaentins A, D, and F, 
and synthetic compounds 11 and 12, and MIC50, MIC90 and MBC values were determined for each 
compound. Chrysophaentin A was again the most potent, with an MIC50 of 5 µM for both clinical 
strains (Table 1), and the MIC90 was only slightly higher at 9 µM. Chrysophaentin A was still 
bacteriostatic at low micromolar concentrations, and the MBC was only 2 times higher at 19 µM. By 
comparison, the symmetrical chrysophaentin F (8) was slightly less active with respective MIC50 and 
MIC90 values of 12 and 37 µM, and was also bacteriostatic at the MIC90. The MIC50s for compounds 
11 and 12 were similar to those of 8 as was the MIC90 for compound 11, while the MIC90 for 
compound 12 was higher. For both synthetic compounds, the MBC was two-fold higher than the 
MIC90. Finally, chrysophaentin D (4) was the least active with MIC50s between 41 and 49 µM, and 
MIC90s at 65 µM.  
Growth curves for chrysophaentins A (1), D (4), and F (8), and compound 12 were graphed as 
percentage growth of untreated bacteria for S. aureus UAMS-1 (Figure 5A) and CA-MRSA  
USA300-LAC (Figure 5B). These curves clearly demonstrate the relationship between the structure of 
the chrysophaentins and analogs, halogen composition, and anti-staphylococcal activity. 
Figure 5. Dose-response curves show the antibacterial activities and reveal a  
structure-activity relationship for the chrysophaentins. Chrysophaentins A (1), D (4), and F (8), 
and fragment 12 were tested for their ability to inhibit the growth of Staphylococcus aureus 
UAMS-1 (panel A) and CA-MRSA USA300-LAC (panel B) in a microbroth dilution assay. 
Plots represent percentage bacterial growth as a function of compound concentration. 
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2.5. Discussion 
C. taylori is a rare marine chrysophyte alga. It was originally discovered in the Dry Tortugas off the 
southern coast of Florida [40], and has since been found in several locations worldwide. Bioactive 
natural products have been discovered from collections made in two locations. The Puerto Rico 
location yielded hormothamnione [41] and 6-desmethoxyhormothamnione [42], while the collections 
from St. John, U.S. Virgin Islands have yielded the ten chrysophaentins, as well as hormothamnione 
and 6-methoxyhormothamnione. As we have described here, analysis of methanol extracts revealed 
geographic variability within the C. taylori collections from St. John. The original collection coming 
from Round Bay in 2007 yielded chrysophaentins A–H. A second collection at Round Bay two years 
later contained a similar profile of compounds, indicating temporal stability in the natural compound 
production at this location. A 2009 collection at Long Bay contained the same eight chrysophaentins in 
a similar ratio. Both Long Bay and Round Bay are on the southeastern side of the island, and each of 
these collections was made in shallow protected waters, where the algae were growing on coral sand. 
The 2009 collection from Hawk’s Nest on the northwestern side of the island yielded a different 
profile of compounds. It was immediately obvious when comparing the chromatograms that the 
difference laid in the complete absence of the asymmetrical chrysophaentins in the samples collected 
at this location. Instead, the most abundant compounds included the acyclic chrysophaentin E, as well 
as two newly identified linear chrysophaentins, namely chrysophaentins E2 and E3. 
Synthetic efforts to obtain a steady supply of chrysophaentin A are under way. An early approach 
that was employed provided two chrysophaentin fragments that we have shown exhibit similar 
potencies and spectrum of activity to those of the parent chrysophaentins. Previously, we profiled the 
anti-staphylococcal activity of several of the natural chrysophaentins towards common laboratory 
strains of S. aureus. In this study, we sought to expand the structure-activity relationship (SAR) by 
including the synthetic fragments, and to expand the number and diversity of S. aureus strains. We 
tested select compounds against five S. aureus strains to measure their potency (MIC50 and MIC90) and 
to determine whether the compounds were bacteriostatic or bactericidal. All chrysophaentins, natural 
and synthetic, were bacteriostatic at their MIC90; but were bactericidal at concentrations ranging from 
two to eight fold higher than their respective MIC90s. Furthermore, the synthetic fragments showed 
similar potency to the acyclic chrysophaentin E (5). 
The synthetic fragments fit perfectly into our proposed structure-activity relationship. The 
tetrachlorinated macrocycle with the asymmetrical linkage between C-16 and C-1′ (chrysophaentin A) 
was essential for maximum potency. Compounds with an ether bond between C-14 and C-1′, which 
lead to a symmetrical macrocycle as seen in chrysophaentin F, show a decrease in overall potency. The 
presence of a fifth halogen at C-12′ did not decrease the antibacterial activity, even when the additional 
halogen was a bromine, indicating that the atom type at this position or even this ring is not critical to 
the observed activity. The absence of a macrocyclic structure, as in chrysophaentin E and the synthetic 
fragments 11 and 12, further decreased antibacterial activity. However, the presence of the 
asymmetrical macrocycle did not guarantee potency as halogen diversity on the phenyl rings also 
affected activity. Chrysophaentin D, which contains two bromines in place of the chlorines on the 
phenol rings in 1, was the least active compound considered in this study. 
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We have shown that subtle changes to the chrysophaentin structure and composition lead to 
differences in antibacterial activity. Knowing that the macrocycle is essential for full antibacterial 
potency, it is not surprising that the synthetic fragments described here have diminished activity 
compared to the cyclic natural products. However, we were gratified to find that they are indeed 
antimicrobial and their activities are comparable to the linear chrysophaentins. Their ease of synthesis 
and antimicrobial activity provide an excellent starting point not only toward the cyclic 
chrysophaentins, but also for generating more elaborate synthetic analogs. 
The biosynthetic pathway leading to production of the chrysophaentins has not been characterized 
and a genome sequence for any Chrysophaeum species has yet to be published. Interestingly, the most 
closely related natural products include the marchantins, bazzanins, and chlorinated isoplagiochins, all 
of which were isolated from different species of liverworts [43]. While these macrocyclic compounds 
are reminiscent of the chrysophaentins, each family possesses defining structural characteristics that 
differ relative to one another and to the chrysophaentins. The marchantins [44] are bisbibenzyl ethers 
whose phenol rings are connected by an ethyl group, and thus far do not contain halogens. The 
bazzanins [45,46] and chlorinated isoplagiochins [47], on the other hand are chlorinated, but are 
bisbibenzyls rather than bisbibenzyl ethers. Like the marchantins and all liverwort metabolites, they 
also contain ethyl linkages. The presence of a butene linkage is unique to the chrysophaentins. While 
some information is known about the biosynthesis of the liverwort metabolites [48], the pathways are 
incompletely characterized; moreover, parallels to chrysophaentin biosynthesis cannot be predicted as 
the producing organisms are not closely related. The lack of biosynthetic information underlines the 
importance of a synthetic approach that could supply large quantities of the chrysophaentins for further 
biological studies. 
3. Experimental Section 
3.1. Biological Material 
Samples of the marine algae were collected from Round Bay in July 2007, and Long Bay, Round Bay, 
and Hawk’s Nest in June 2009, St. John, U.S. Virgin Islands (Collection permit VIIS-2008-SCI-0034 
National Park Service). Each of the alga samples were observed as fluffy, sulfur yellow colonies 
growing on coarse sand at shallow depths averaging −20 ft. The samples were identified as 
Chrysophaeum taylori Lewis and Bryan as described previously [27]. Briefly, the presence of clear 
stalk like structures made up of branching mucilaginous “streamers” of pear shaped, invaginated cells 
were visible by light microscopy (4–10×) on freshly collected specimens, as well as those preserved in 
2.5% glutaraldehyde in sterile sea water immediately after collection. 
3.2. LC-MS 
Lyophilized material was sequentially extracted with hexanes, CH2Cl2, and MeOH. The MeOH 
extract was analyzed by reverse-phase HPLC with an MS detector (Jupiter Proteo C12, 250 × 4.6 mm, 
4 µm, DAD at 220 and 280 nm, flow rate 0.5 mL/min) eluting with a linear gradient of 50–80% 
methanol in 0.05% TFA-water in 50 min. 
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3.3. Mass Spectrometry and MS/MS Fragmentation 
The MeOH extract was partitioned between n-BuOH–H2O (1:1), and the organic layer was 
fractionated on Sephadex LH-20. Fractions containing the unknown chrysophaentins were subjected to 
HR-ESI-MS and MS in-source fragmentation. High resolution accurate mass data was obtained using a 
Waters LCT Premiere ESI-TOF mass spectrometer equipped with a Z-Spray electrospray ion source. 
The instrument was operated in the w-mode at a nominal resolution of 10,000 and an internal standard 
was used as reference. The ionization mode was negative ion and the ESI capillary voltage was −3000 V 
and the cone voltage was 30 V. The collisionally activated dissociation (CAD) mass spectra were 
obtained using a Waters LCT Premiere ESI-TOF mass spectrometer according to the method described 
by Ren et al. [49] The ion guide 1 voltage was 65 V and the cone voltage was 30 V. The instrument 
was operated in negative ion mode. 
3.4. General Synthesis 
All moisture sensitive reactions were performed using syringe-septum techniques under an 
atmosphere of either dry N2 or dry argon unless otherwise noted. All glassware was dried in an oven at 
140 °C for a minimum of 6 h or flame-dried under an atmosphere of dry nitrogen prior to use. 
Reactions carried out at −78 °C employed a CO2(s)/acetone bath. Et2O and tetrahydrofuran were dried 
by distillation over sodium/benzophenone under an argon atmosphere. Dry methylene chloride was 
purified by filtration through an activated alumina column. All degassed solvents were prepared using 
the freeze/pump/thaw method (3×). Methanol, acetonitrile, and N,N-dimethylformamide were stored 
over molecular sieves (3 Å). Deuterated chloroform was stored over anhydrous potassium carbonate. 
Reactions were monitored by TLC analysis (pre-coated silica gel 60 F254 plates, 250 µm layer thickness) 
and visualized by using UV lamp (254 nm) or by staining with either Vaughn’s reagent (4.8 g of 
(NH4)6Mo7O24·4H2O and 0.2 g of Ce(SO4)2 in 100 mL of a 3.5 N H2SO4) or a potassium permanganate 
solution (1.5 g of KMnO4 and 1.5 g of K2CO3 in 100 mL of a 0.1% NaOH solution). Flash column 
chromatography was performed with 40–63 µm silica gel (Silicycle). Microwave reactions were 
performed on a Biotage Initiator microwave reactor. Infrared spectra were measured on a Smiths 
Detection IdentifyIR FT-IR spectrometer (ATR). Unless otherwise indicated, all NMR data were 
collected at room temperature in CDCl3 or (CD3)2CO on a 300, 400, 500, 600, or 700 MHz Bruker 
instrument. Chemical shifts (δ) are reported in parts per million (ppm) with internal CHCl3 (δ 7.26 ppm 
for 
1
H and 77.00 ppm for 
13
C), or internal acetone (δ 2.05 ppm for 1H and 29.85 ppm for 13C), as the 
reference. 
1
H NMR data are reported as follows: chemical shift, multiplicity (s = singlet, bs = broad 
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublets, dt = doublet of 
triplets, td = triplet of doublets, qd = quartet of doublets, sep = septet), integration, and coupling 
constant(s) (J) in Hertz (Hz). 
3,5-Dimethoxy benzyl alcohol (18) [29]. To a stirred suspension of lithium aluminum hydride (13.1 g, 
329 mmol, 2 equiv) in dry THF (400 mL) at 0 °C was added a solution of 3,5-dimethoxybenzoic acid 
(30.0 g, 164 mmol, 1 equiv) in dry THF (400 mL) over 45 min. Upon completion of the addition, the 
reaction mixture was diluted with THF (300 mL), warmed to rt, stirred for 5 h, and slowly quenched 
with a saturated aqueous solution of Na/K tartrate. The resulting biphasic mixture was stirred at r.t. for 
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1 h, the organic layer was separated, the remaining aqueous layer was extracted with EtOAc (×2), and 
the combined organic layers were dried (MgSO4), filtered, and concentrated under reduced pressure to 
give 27.0 g (97%) of 18 as a colorless oil: Rf 0.33 (EtOAc/hexanes, 1:2); IR (CDCl3) 3390, 2937, 
1594, 1456, 1428, 1318, 1294, 1202, 1146, 1057, 829 cm
−1
; 
1
H NMR (600 MHz, CDCl3) δH 6.45  
(d, 2 H, J = 2.4 Hz), 6.32 (d, 1 H, J = 2.4 Hz), 4.50 (d, 2 H, J = 5.4 Hz), 3.71 (s, 6 H), 3.49 (t, 1 H,  
J = 5.4 Hz); 
13
C NMR (150 MHz, CDCl3) δC 160.5, 143.3, 104.2, 99.2, 64.5, 55.0. 
3,5-Dimethoxybenzyl bromide (19) [29]. To a stirred solution of 18 (17.5 g, 104 mmol, 1 equiv) in 
CH2Cl2 (500 mL) at 0 °C was added dropwise PBr3 (12.1 mL, 125 mmol, 1.2 equiv). The reaction 
mixture was slowly warmed to rt, stirred for 3 h, quenched with a saturated aqueous solution of 
NaHCO3, and stirred at r.t. for 1 h. The organic layer was separated and the aqueous layer was 
extracted with Et2O. The combined organic layers were dried (MgSO4), filtered, and concentrated 
under reduced pressure to give 22.2 g (92%) of 19 as a white solid: Rf 0.75 (EtOAc/hexanes, 1:2);  
IR (CDCl3) 2999, 2954, 1596, 1458, 1428, 1345, 1323, 1297, 1204, 1152, 1062, 930 cm
−1
; 
1
H NMR 
(400 MHz, CDCl3) δH 6.54 (d, 2 H, J = 2.0 Hz), 6.39 (d, 1 H, J = 2.4 Hz), 4.42 (s, 2 H), 3.80 (s, 6 H); 
13
C NMR (150 MHz, CDCl3) δC 160.9, 139.7, 107.0, 100.6, 55.4, 33.6; HRMS (ESI
+
) m/z calcd for 
C9H12O2Br 231.0021, found 231.0038. 
(3-(3,5-Dimethoxyphenyl)prop-1-ynyl)trimethylsilane (20). To a stirred solution of ethynyl 
trimethysilane (39.1 mL, 277 mmol, 4 equiv) in THF (120 mL) at 0 °C was added ethylmagnesium 
bromide (3.16 M in Et2O; 87.6 mL, 277 mmol, 4 equiv). The reaction was warmed to rt, stirred for  
30 min, and CuBr (9.93 g, 69.2 mmol, 1 equiv) was added. The reaction was stirred at r.t. for 15 min, 
3,5-dimethoxybenzyl bromide (19, 16.0 g, 69.2 mmol, 1 equiv) was added, the resulting mixture was 
heated to 66 °C, and stirred overnight. The reaction mixture was diluted with Et2O, slowly quenched 
with brine, and extracted with Et2O (×2). The combined organic layers were washed with a saturated 
aqueous solution of NH4Cl, brine, dried (MgSO4), filtered, and concentrated under reduced pressure. 
The crude mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 1:10) to give 17.2 g 
(100%) of 20 as a pale yellow oil: Rf 0.41 (EtOAc/hexanes, 1:20); IR (neat) 2956, 2898, 2175, 1754, 
1596, 1459, 1428, 1204, 1156, 1122, 1101, 839 cm
-1
; 
1
H NMR (400 MHz, CDCl3) δH 6.53 (d, 2 H,  
J = 2.4 Hz), 6.34 (t, 1 H, J = 2.4 Hz), 3.79 (s, 6 H), 3.60 (s, 2 H), 0.19 (s, 9 H); 
13
C NMR (100 MHz, 
CDCl3) δC 160.8, 138.7, 105.9, 104.0, 98.7, 87.1, 55.3, 26.3, 0.1; HRMS (ESI
+
) m/z calcd for 
C14H21O2Si 249.1311, found 249.1287. 
1,3-Dimethoxy-5-(prop-2-ynyl)benzene (15). To a stirred solution of 20 (5.37 g, 21.6 mmol, 1 equiv) 
and AcOH (4.99 mL, 86.5 mmol, 4 equiv) in THF (100 mL) was added dropwise TBAF (1 M in THF; 
86.5 mL, 86.5 mmol, 4 equiv). The resulting reaction mixture was stirred at r.t. for 24 h, diluted with 
Et2O, washed with brine (×2), dried (MgSO4), filtered, and concentrated under reduced pressure.  
The crude mixture was purified by chromatography on SiO2 (EtOAc/hexanes, 1:10) to give 3.85 g 
(100%) of 15 as a colorless oil: Rf 0.36 (EtOAc/hexanes, 1:10); IR (CDCl3) 3286, 2999, 2954, 1593, 
1457, 1428, 1344, 1323, 1288, 1204, 1154, 1064, 827; 
1
H NMR (400 MHz, CDCl3) δH 6.53 (d, 2 H,  
J = 2.4 Hz), 6.35 (t, 1 H, J = 2.4 Hz), 3.79 (s, 6 H), 3.56 (d, 2 H, J = 2.8 Hz), 2.20 (t, 1 H, J = 2.8 Hz); 
13
C NMR (100 MHz, CDCl3) δC 160.9, 138.3, 105.9, 98.7, 81.7, 70.6, 55.3, 25.0; HRMS (EI
+
)  
m/z calcd for C11H12O2 176.0837, found 176.0834. 
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5-(Prop-2-ynyl)-1,3-phenylene bis(2,2-dimethylpropanoate (21). To a stirred solution of 15 (6.50 g, 
36.9 mmol, 1 equiv) in CH2Cl2 (1200 mL) at 0 °C was added BBr3 (1 M in CH2Cl2; 92.2 mL, 
92.2 mmol, 5 equiv) over 1 h via an addition funnel. The reaction mixture was warmed to r.t. and 
stirred overnight. The reaction mixture was slowly quenched with a saturated aqueous solution of 
NaHCO3 (500 mL) and stirred at r.t. for 4 h. The solution was acidified with HCl, extracted with 
CH2Cl2 and EtOAc, and the combined organic layers were dried (MgSO4), filtered, and concentrated 
under reduced pressure. The crude mixture was dissolved in CH2Cl2 (180 mL), and triethylamine 
(20.9 mL, 148 mmol, 4 equiv) and PivCl (11.6 mL, 92.2 mmol, 2.5 equiv) were added. The resulting 
solution was stirred at r.t. for 90 min, diluted with brine, the organic layer was separated, and the 
aqueous layer was extracted with EtOAc. The combined organic layers were dried (MgSO4), filtered, 
and concentrated under reduced pressure. The crude mixture was purified by chromatography on SiO2 
(EtOAc/hexanes, 1:10) to give 9.6 g (82%) of 21 as a colorless oil: Rf 0.85 (EtOAc/hexanes, 3:7);  
IR (neat) 3293, 2973, 1806, 1750, 1414, 1452, 1396, 1366, 1269, 1118, 1098, 1031, 1003 cm
−1
;  
1
H NMR (300 MHz, CDCl3) δH 6.95 (d, 2 H, J = 1.8 Hz), 6.76 (t, 1 H, J = 1.8 Hz), 3.61 (d, 2 H,  
J = 2.4 Hz), 2.21 (t, 1 H, J = 2.4 Hz); 
13
C NMR (75 MHz, CDCl3) δC 176.6, 151.5, 138.3, 118.3, 113.8, 
80.7, 71.2, 39.1, 27.1, 24.5; HRMS (EI
+
) m/z calcd for C19H24O4 316.1675, found 316.1670. 
4-Chloro-2,5-dimethoxybenzaldehyde (16) [33,34]. To a stirred solution of 2-chloro-1,4-dimethoxy 
benzene (25.0 g, 0.145 mol, 1 equiv) and hexamethylene tetramine (20.5 g, 0.145 mol, 1 equiv) at r.t. 
was carefully added TFA (250 mL). The resulting yellow suspension was heated to 95 °C, stirred for 
5 h, and the hot brown solution was poured into a 2 L Erlenmeyer flask containing approximately 
250 g of crushed ice. To the vigorously stirred mixture was slowly added solid NaHCO3 (243 g, 
2.90 mol, 20 equiv) in 5–10 g portions over two hours. The resulting yellow precipitate was filtered 
through a pad of celite, washed with water, and dissolved in Et2O. The organic layer was washed with 
water and brine, dried (MgSO4), filtered, and concentrated under reduced pressure to yield 29.0 g 
(100%) of 16 as an off-white solid: Rf 0.70 (EtOAc/hexanes, 3:7); IR (neat) 2941, 2874, 1664, 1601, 
1575, 1497, 1478, 1461, 1389, 1269, 1213, 1023, 977 cm
−1
; 
1
H NMR (400 MHz, CDCl3) δH 10.35  
(s, 1 H), 7.33 (s, 1 H), 7.03 (s, 1 H), 3.87 (s, 6 H); 
13
C NMR (100 MHz, CDCl3) δC 188.4, 156.1, 149.4, 
130.4, 123.4, 114.5, 109.9, 56.5, 56.3; HRMS (EI
+
) m/z calcd for C9H9O3Cl 200.0240, found 200.0238. 
(4-Chloro-2,5-dimethoxyphenyl)methanol (25). To a stirred solution of 16 (29.0 g, 145 mmol,  
1 equiv) in absolute ethanol (550 mL) was added sodium borohydride (27.3 g, 723 mmol, 5 equiv). 
The reaction mixture was stirred at r.t. for 6 h, quenched via dropwise addition of acetone, diluted with 
EtOAc, washed with brine (×2), dried (MgSO4), filtered, and concentrated under reduced pressure. The 
crude residue was purified by chromatography on SiO2 (EtOAc/hexanes, 1:1) to give 28.0 g (96%) of 
25 as a white solid: mp 89–90 °C; Rf 0.53 (EtOAc/hexanes, 1:1); IR (neat) 3258, 2958, 2915, 1495, 
1461, 1392, 1204, 1061, 719 cm
−1
; 
1
H NMR (300 MHz, CDCl3) δH 6.90 (s, 1 H), 6.80 (s, 1 H), 4.55  
(d, 2 H, J = 4.2 Hz), 3.77 (s, 3 H), 3.71 (s, 3 H), 3.10 (bs, 1 H); 
13
C NMR (75 MHz, CDCl3) δC 150.6, 
148.7, 128.4, 120.8, 112.5, 112.4, 60.3, 56.5, 55.6; HRMS (ESI
+
) m/z calcd for C9H12O3Cl 203.0475, 
found 203.0465. 
1-(Bromomethyl)-4-chloro-2,5-dimethoxybenzene (26) [50]. To a stirred solution of 25 (5.00 g, 
24.7 mmol, 1 equiv) in CH2Cl2 (125 mL) at 0 °C was added dropwise HBr (47–49% aqueous solution; 
4.13 mL, 74.0 mmol, 3 equiv). The resulting solution was slowly warmed to r.t. and stirred overnight. 
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The following morning a second batch of HBr (47–49% solution; 4.13 mL, 74.0 mmol, 3 equiv) was 
added to the reaction mixture, which was stirred at r.t. for an additional 4 h, extracted with Et2O (×2), 
washed with water, a saturated aqueous solution of NaHCO3, brine, dried (MgSO4), filtered, and 
concentrated under reduced pressure to give 6.55 g (100%) of 26 as a white solid: Rf 0.31 
(EtOAc/hexanes, 3:7); IR (neat) 2962, 2947, 2844, 1732, 1582, 1495, 1458, 1443, 1389, 1301, 1204, 
1182, 1033, 882 cm
−1
; 
1
H NMR (400 MHz, CDCl3) δH 6.91–6.90 (m, 2 H), 4.50 (s, 2 H), 3.84 (s, 3 H), 
3.82 (s, 3 H); 
13
C NMR (75 MHz, CDCl3) δC 151.3, 148.9, 125.1, 123.2, 114.6, 113.6, 56.6, 56.2, 28.2. 
(E)-5-(2-Chloro-3-iodoallyl)-1,3-phenylene bis(2,2-dimethylpropanoate (22) and (Z)-5-(2-Chloro-
3-iodoallyl)-1,3-phenylene bis(2,2-dimethylpropanoate (23). To a stirred solution of 21 (9.50 g, 
30.0 mmol, 1 equiv) in dry CH2Cl2 (150 mL) at 0 °C was added ICl (1 M in CH2Cl2; 30.0 mL, 
30.0 mmol, 1 equiv). The reaction mixture was warmed to rt, stirred protected from light (enclosed in 
aluminum foil) for 3 h, diluted with Et2O, washed with Na2SO4 (×2), brine, dried (MgSO4), filtered, 
and concentrated under reduced pressure. The crude mixture was purified by chromatography on SiO2 
(EtOAc/hexanes, 1:10) to give an inseparable 2:1 mixture of 22 and 23 (13.7 g, 95%) as a colorless oil: 
Rf 0.54 (EtOAc/hexanes, 1:10); IR (neat) 3277, 2934, 2872, 1746, 1592, 1497, 1461, 1409, 1269, 
1207, 1122, 1103, 1032, 975, 723 cm
−1
; HRMS (ESI
+
) m/z calcd for C19H24O4NaClI 501.0306, found 
501.0308. Characteristic data for the major, desired isomer 22: 
1
H NMR (300 MHz, CDCl3) δH 6.87  
(d, 2 H, J = 1.5 Hz), 6.80 (t, 1 H, J = 2.1 Hz), 6.62 (s, 1 H), 3.90 (s, 2 H), 1.35 (s, 18 H); 
13
C NMR 
(100 MHz, CDCl3) δC 176.6, 151.6, 137.9, 135.6, 119.0, 114.2, 74.8, 44.2, 39.1, 27.1. Characteristic 
signals for 23: 
1
H NMR (300 MHz, CDCl3) δH 7.06 (s, 1 H), 3.92 (s, 2 H). 
(E)-5-(2-Chloro-4-(4-chloro-2,5-dimethoxyphenyl)but-2-enyl)benzene-1,3-diol (11). A flame-dried 
microwave vial was charged with a 2:1 mixture of 22 and 23 (0.520 g, 1.08 mmol, 1 equiv), Pd(OAc)2 
(0.0122 g, 0.0543 mmol, 0.05 equiv), P(o-tol)3 (0.0341 g (0.109 mmol, 0.1 equiv), and freshly 
distilled, dry, degassed DMF (0.8 mL). The reaction mixture was stirred at r.t. for 10 min. In a separate 
dry flask, a catalytic amount of iodine (~20 mg) and zinc (0.362 g, 5.43 mmol, 5 equiv) were heated 
(bunsen burner) until a purple gas coated the interior of the flask. The flask was cooled to rt, charged 
with distilled, dry, degassed DMF (1 mL), and benzyl bromide 26 (1.15 g, 4.34 mmol, 4 equiv). The 
mixture was allowed to stir at r.t. under argon for 6 min. The activated organozinc reagent was filtered 
through an oven dried fritted funnel under an atmosphere of argon and cannulated into the stirred 
solution of 22 and 23. The resulting solution was heated in a microwave reactor (2 min, 120 °C), 
treated with a second batch of Pd(OAc)2 (0.0122 g, 0.0543 mmol, 0.05 equiv) and resubjected to the 
microwave conditions (2 min, 120 °C). The crude reaction mixture was directly purified by 
chromatography on SiO2 (EtOAc/hexanes, 1:20) to give a crude yellow oil which was immediately 
dissolved in MeOH/CH2Cl2 (4 mL, 2:1), and Cs2CO3 (1.67 g, 5.08 mmol, 5 equiv) was added. The 
reaction mixture was stirred at r.t. for 6 h, diluted with EtOAc, and acidified with conc. HCl. The 
organic layer was separated, and the acidified aqueous solution was extracted with EtOAc. The 
combined organic layers were washed with brine, dried (MgSO4), filtered, and concentrated under 
reduced pressure. The crude mixture was purified by chromatography on SiO2 (chloroform/acetone, 
8:2) to give a 2:1 mixture of 11 and the undesired regioisomer 27 (0.192 g, 51%) as a yellow oil. 
Characteristic signals for 27: 
1
H NMR (600 MHz (CD3)2CO) δH 8.20 (bs, 2 H), 7.02 (d, 2 H, J = 3.6 Hz), 
6.45 (t, 1 H, J = 7.8 Hz), 6.26 (s, 3 H), 3.84 (app s, 5 H), 3.81 (s, 3 H), 3.50 (d, 2 H, J = 7.8 Hz);  
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13
C NMR (150 MHz, CDCl3) δC 159.5, 152.3, 150.0, 141.5, 140.7, 127.7, 120.9, 115.6, 113.8, 108.1, 
101.9, 101.7, 56.9, 56.5, 45.1. 
An analytically pure sample of 11 for biological evaluation and characterization was obtained  
via SFC chromatography using a semiprep (250 × 10 mm) silica column (Rt 5.80 min, 10 mL/min, 
15% methanol, 220 nm detection): Rf 0.48 (acetone/chloroform, 2:8); IR (acetone) 3375, 3001, 2952, 
1696, 1599, 1495, 1463, 1387, 1212, 1156, 1034, 1010 cm
−1
; 
1
H NMR (600 MHz (CD3)2CO) δH 8.18 
(bs, 2 H), 7.02 (s, 1 H), 6.99 (s, 1 H), 6.30 (s, 2 H), 6.25 (s, 1 H), 5.88 (t, 1 H, J = 7.8 Hz), 3.84 (s, 3 H), 
3.81 (s, 3 H), 3.73 (s, 2 H), 3.51 (d, 2 H, J = 7.8 Hz); 
13
C NMR (150 MHz, CDCl3) δC 159.5, 152.3, 
150.0, 140.6, 133.7, 128.1, 128.1, 120.8, 115.5, 113.8, 108.0, 101.8, 56.9, 56.5, 40.2, 29.5; HRMS 
(ES
−
) [M + Cl]
−
 m/z calcd for C18H18O4Cl3 403.0271, found 403.0295. 
(E)-5-(2-Chloro-4-(4-chloro-2,5-dihydroxyphenyl)but-2-enyl)benzene-1,3-diol (12). A stirred 
solution of 11 (0.0500 g, 0.135 mmol, 1 equiv) in CH2Cl2 (7 mL) was enclosed in aluminum foil  
and cooled to 0 °C. To the stirred solution was added dropwise BBr3 (1 M in CH2Cl2; 0.677 mL, 
0.677 mmol, 5 equiv). The resulting solution was slowly warmed to r.t. and stirred overnight. The 
reaction mixture was quenched with a saturated aqueous solution of NaHCO3 (8 mL) and stirred at r.t. 
for an additional hour. The solution was acidified with HCl, extracted with EtOAc (×2) and the 
combined organic layers were dried (MgSO4), filtered, and concentrated under reduced pressure. The 
crude product was purified by chromatography on SiO2 (chloroform/acetone, 3:1) to give 12 (0.0462 g, 
96%) as a slightly yellow film. Before submission for biological testing, a sample of 12 was further 
purified via SFC chromatography using a semiprep (250 × 10 mm) silica column (Rt 4.68 min,  
8 mL/min, 25% methanol, 220 nm detection): Rf 0.15 (acetone/chloroform, 2:8); IR (neat) 3343, 1692, 
1599, 1495, 1417, 1329, 1184, 1143, 1005, 822 cm
−1
; 
1
H NMR (600 MHz (CD3)2CO) δH 8.17 (bs, 4 H), 
6.86 (s, 1 H), 6.84 (s, 1 H), 6.29 (d, 2 H, J = 2.4 Hz), 6.24 (t, 1 H, J = 2.4 Hz), 5.89 (t, 1 H, J = 7.8 Hz), 
3.69 (s, 2 H), 3.47 (d, 2 H, J = 7.8 Hz); 
13
C NMR (150 MHz, CDCl3) δC 159.5, 149.0, 146.9, 140.5, 
133.8, 128.0, 127.0, 118.5 (2C), 116.7, 108.0, 101.8, 40.2, 29.5; HRMS (ES
−
) [2M − H]− m/z calcd for 
C32H27O8Cl4 679.0460, found 679.0482. 
The demethylation reaction was also performed on a 2:1 mixture of 11 and 27, resulting in a  
2:1 mixture of 12 and its (Z)-diastereomer. Characteristic signals for the (Z)-diastereomer: 
1
H NMR 
(400 MHz (CD3)2CO) δH 6.85 (s, 1 H), 6.48 (t, 1 H, J = 7.6 Hz), 3.81 (s, 2 H), 3.46 (d, 2 H, J = 7.6 Hz). 
3.5. Anti-Staphylococcal Activity 
Microbroth dilution assays were performed as described in the CLSI guidelines. Minimum 
inhibitory concentrations (MIC50 and MIC90) were determined using 96-well microbroth dilution 
assays. Antimicrobial activity of pure compounds or antibiotic standards were tested by adding serial 
dilutions to wells containing Mueller Hinton II broth. An overnight growth of S. aureus ATCC 25923, 
MRSA ATCC BAA-41, MDRSA BAA-44, S. aureus UAMS-1, and CA-MRSA USA300-LAC was 
diluted in Mueller-Hinton II broth and added to the wells to a final concentration of 5 × 10
5
 colony 
forming units (CFU) per milliliter. Plates were incubated for 18 h at 37 °C with shaking at 200 rpm. 
Absorbance at 600 nm is read on a Molecular Devices plate reader. Growth curves are plotted, and 
curves were fit to a one-site model using the equation y = 100/[1 + (concentration/MIC50)], where 
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MIC50 is the concentration at which the growth of bacterial cultures are reduced by 50%. MIC90 values 
were visually calculated by determining the lowest concentration of test compound that allowed no 
visible growth (no difference of absorption between treated samples and blank controls). 
Bacteriostatic (BS) or bactericidal (BC) properties were determined by plating onto a fresh TSA 
plate an aliquot from each well that showed no visible growth starting at the MIC90. Plates were 
incubated for 24 h at 37 °C, and colonies were counted. Bactericidal concentrations were defined as 
those that resulted in a three logarithmic decrease in the number of viable bacteria relative to the 
starting inoculum, and the lowest bactericidal concentration was defined as the MBC. 
4. Conclusions 
The rare marine chrysophyte alga C. taylori has yielded a number of biologically active natural 
products. While the occurrence of C. taylori has been documented at a growing number of locations 
globally, thus far only collections obtained from the southeastern side of St. John appear to contain the 
full suite of chrysophaentins. The geographical variability described here, along with temporal and 
seasonal changes in the abundance of C. taylori, limited our ability to obtain additional material for 
study. Nevertheless, early synthetic efforts toward the synthesis of chrysophaentin A in particular have 
provided fragments of the natural products that have proven useful for biological studies. Here we 
have expanded the antimicrobial studies of several chrysophaentins and two synthetic fragments to 
include drug-susceptible and drug-resistant S. aureus strains that are of current clinical interest. 
Although approximately half the size of the cyclic chrysophaentins, we have shown that the potencies 
and spectrum of antimicrobial activity of the synthetic fragments are comparable to those of the parent 
chrysophaentins, in particular to the acyclic compound chrysophaentin E. Moreover, both the natural 
products and synthetic fragments are equally effective against both drug-resistant and drug-susceptible 
S. aureus strains. In summary, our results show promise for the notion of synthesizing equally potent 
chrysophaentin analogs that will be more readily available, and provide new data on the antimicrobial 
spectrum of this novel class of antibiotics. 
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